Sonnet Biotherapeutics Inc. Enters Into Licensing Agreement With Alkem Laboratories Limited to Develop and Commercialize Son-080 for Diabetic Peripheral Neuropathy (Dpn) in India
Sonnet生物製藥公司與Alkem實驗室有限公司達成許可協議,用於開發和商業化Son-080,用於治療印度糖尿病周圍神經病變(DPN)
Sonnet Biotherapeutics Inc. Enters Into Licensing Agreement With Alkem Laboratories Limited to Develop and Commercialize Son-080 for Diabetic Peripheral Neuropathy (Dpn) in India
Sonnet生物製藥公司與Alkem實驗室有限公司達成許可協議,用於開發和商業化Son-080,用於治療印度糖尿病周圍神經病變(DPN)
譯文內容由第三人軟體翻譯。